2023 -- H 5922 | |
======== | |
LC002079 | |
======== | |
STATE OF RHODE ISLAND | |
IN GENERAL ASSEMBLY | |
JANUARY SESSION, A.D. 2023 | |
____________ | |
A N A C T | |
RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT | |
| |
Introduced By: Representatives Hull, Phillips, Diaz, Noret, DeSimone, Fogarty, Abney, | |
Date Introduced: March 01, 2023 | |
Referred To: House Judiciary | |
(Attorney General) | |
It is enacted by the General Assembly as follows: | |
1 | SECTION 1. Section 21-28-2.08 of the General Laws in Chapter 21-28 entitled "Uniform |
2 | Controlled Substances Act" is hereby amended to read as follows: |
3 | 21-28-2.08. Contents of schedules. |
4 | Schedules I through V shall consist of the drugs and other substances, by whatever official |
5 | name, common or usual name, chemical name, or brand name designated, listed in the |
6 | corresponding section, or designated by the director of the department of health pursuant to § 21- |
7 | 28-2.01. |
8 | Schedule I |
9 | (a) Schedule I shall consist of the drugs and other substances, by whatever official name, |
10 | common or usual name, chemical name, or brand name designated, listed in this section. |
11 | (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the |
12 | following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers |
13 | whenever the existence of the isomers, esters, ethers, and salts is possible within the specific |
14 | chemical designation: |
15 | (1) Acetylmethadol |
16 | (2) Allylprodine |
17 | (3) Alphacetylmethadol |
18 | (4) Alphameprodine |
19 | (5) Alphamethadol |
| |
1 | (6) Benzethidine |
2 | (7) Betacetylmethadol |
3 | (8) Betameprodine |
4 | (9) Betamethadol |
5 | (10) Betaprodine |
6 | (11) Clonitazene |
7 | (12) Dextromoramide |
8 | (13) Difenoxin |
9 | (14) Diampromide |
10 | (15) Diethylthiambutene |
11 | (16) Dimenoxadol |
12 | (17) Dimepheptanol |
13 | (18) Dimethylthiambutene |
14 | (19) Dioxaphetyl butyrate |
15 | (20) Dipipanone |
16 | (21) Ethylmethylthiambutene |
17 | (22) Etonitazene |
18 | (23) Extoxerdine |
19 | (24) Furethidine |
20 | (25) Hydroxypethidine |
21 | (26) Ketobemidone |
22 | (27) Levomoramide |
23 | (28) Levophenacylmorphan |
24 | (29) Morpheridine |
25 | (30) Noracymethadol |
26 | (31) Norlevorphanol |
27 | (32) Normethadone |
28 | (33) Norpipanone |
29 | (34) Phenadoxone |
30 | (35) Phenampromide |
31 | (36) Phenomorphan |
32 | (37) Phenoperidine |
33 | (38) Piritramide |
34 | (39) Proheptazine |
| LC002079 - Page 2 of 18 |
1 | (40) Properidine |
2 | (41) Propiram |
3 | (42) Racemoramide |
4 | (43) Trimeperidone |
5 | (44) Tilidine |
6 | (45) Alpha-methylfentanyl |
7 | (46) Beta-hydroxy-3-methylfentanyl other names: |
8 | N-[1-(2hydroxy-2-phenethyl)-3-methyl-4piperidingyl]-Nphenylpropanamide |
9 | (47) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N- |
10 | phenylpropanamide) |
11 | (48) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide, its optical, positional, and |
12 | geometric isomers, salts and salts of isomers (Other names: acetyl fentanyl) |
13 | (49) N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenyl propionamide |
14 | (Other names: beta-hydroxythiofentanyl) |
15 | (50) N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide (Other names: Butyryl fentanyl) |
16 | (51) N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide (Other names: Furanyl |
17 | fentanyl) |
18 | (52) 3,4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]benzamide (Other names: AH- |
19 | 7921) |
20 | (53) 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (Other names: |
21 | U-47700) |
22 | (54) 3-Methylbutyrfentanyl (Other names: 3-MBF) |
23 | (55) 4-Fluorobutyrfentanyl (Other names: 4-FBF, p-FBF) |
24 | (56) 4-Phenylfentanyl |
25 | (57) 4-Methoxybutyrfentanyl (Other names: 4-MeO-BF) |
26 | (58) Acrylfentanyl (Other names: acryloyfentanyl) |
27 | (59) Lofentanyl |
28 | (60) N-Methylcarfentanyl |
29 | (61) Ocfentanyl (INN, A-3217) |
30 | (63) 4-methoxymethylfentanyl (Other names: R-30490) |
31 | (64) 1-cyclohexyl-4-(1,2 diphenylethyl)piperazine) (Other names: MT-45, IC-6) |
32 | (c)(b) Opium Derivatives. Unless specifically excepted or unless listed in another schedule, |
33 | any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the |
34 | existence of the salts, isomers, and salts of isomers is possible within the specific chemical |
| LC002079 - Page 3 of 18 |
1 | designation: |
2 | (1) Acetorphine |
3 | (2) Acetyldihydrocodeine |
4 | (3) Benzylmorphine |
5 | (4) Codeine methylbromide |
6 | (5) Codeine-N-Oxide |
7 | (6) Cyprenorphine |
8 | (7) Desomorphine |
9 | (8) Dihydromorphine |
10 | (9) Etorphine (Except hydrochloride salt) |
11 | (10) Heroin |
12 | (11) Hydromorphinol |
13 | (12) Methyldesorphine |
14 | (13) Methylihydromorphine |
15 | (14) Morphine methylbromide |
16 | (15) Morphine methylsulfonate |
17 | (16) Morphine-N-Oxide |
18 | (17) Myrophine |
19 | (18) Nococodeine |
20 | (19) Nicomorphine |
21 | (20) Normorphine |
22 | (21) Pholcodine |
23 | (22) Thebacon |
24 | (23) Drotebanol |
25 | (d)(c) Hallucinogenic Substances. Unless specifically excepted or unless listed in another |
26 | schedule, any material, compound, mixture, or preparation that contains any quantity of the |
27 | following hallucinogenic substances, or that contains any of its salts, isomers, and salts of isomers |
28 | whenever the existence of the salts, isomers, and salts of isomers is possible within the specific |
29 | chemical designation (for purposes of this subsection only, the term “isomer” includes the optical, |
30 | position, and geometric isomers): |
31 | (1) 3, 4-methylenedioxy amphetamine |
32 | (2) 5-methoxy-3, 4-methylenedioxy amphetamine |
33 | (3) 3, 4, 5-trimethoxy amphetamine |
34 | (4) Bufotenine |
| LC002079 - Page 4 of 18 |
1 | (5) Diethyltryptamine |
2 | (6) Dimethyltryptamine |
3 | (7) 4-methyl 2, 5-dimethoxyamphetamine |
4 | (8) Ibogaine |
5 | (9) Lysergic acid diethylamide |
6 | (10) Marihuana |
7 | (11) Mescaline |
8 | (12) Peyote. Meaning all parts of the plant presently classified botanically as Lophophora |
9 | Williamsii Lemair whether growing or not; the seeds of the plant; any extract from any part of the |
10 | plant; and any compound, manufacture, salt, derivative, mixture, or preparation of the plant, its |
11 | seeds or extracts. |
12 | (13) N-ethyl-3-piperidyl benzilate |
13 | (14) N-methyl-3-piperidyl benzilate |
14 | (15) Psilocybin |
15 | (16) Psilocyn |
16 | (17) Tetrahydrocannabinols. Synthetic equivalents of the substances contained in the plant, |
17 | or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives, and their |
18 | isomers with similar chemical structure and pharmacological activity such as the following: delta |
19 | 1 cis or trans tetrahydrocannabinol, and their optical isomers. Delta 6 cis or trans |
20 | tetrahydrocannabinol and their optical isomers. Delta 3, 4 cis or trans tetrahydrocannabinol and |
21 | their optical isomer. (Since nomenclature of these substances is not internationally standardized, |
22 | compounds of these structures, regardless of numerical designation of atomic positions covered). |
23 | (18) Thiophene analog of phencyclidine. 1-(1-(2 thienyl) cyclo-hexyl) pipiridine: 2- |
24 | Thienyl analog of phencyclidine: TPCP |
25 | (19) 2,5 dimethoxyamphetamine |
26 | (20) 4-bromo-2,5-dimethoxyamphetamine, 4-bromo-2,5-dimethoxy-alpha- |
27 | methylphenethyamine: 4-bromo-2,5-DMA |
28 | (21) 4-methoxyamphetamine-4-methoxy-alpha-methylphenethylaimine: |
29 | paramethoxyamphetamine: PMA |
30 | (22) Ethylamine analog of phencyclidine. N-ethyl-1-phenylcyclohexylamine, (1- |
31 | phenylcyclohexyl) ethylamine, N-(1-phenylcyclophexyl) ethylamine, cyclohexamine, PCE |
32 | (23) Pyrrolidine analog of phencyclidine. 1-(1-phencyclohexyl)-pyrrolidine PCPy, PHP |
33 | (24) Parahexyl; some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9- |
34 | trimethyl-6H-dibenz o (b,d) pyran: Synhexyl. |
| LC002079 - Page 5 of 18 |
1 | (25) Salvia Divinorum (Salvinorin A or Divinorin A), meaning any extract from any part |
2 | of the plant, and any compound, salt derivative, or mixture of the plant or its extracts. This shall |
3 | not mean the unaltered plant. |
4 | (26) Datura stamonium (jimsom weed or datura), meaning any extract from any part of the |
5 | plant, and any compound, salt derivative, or mixture of the plant or its extracts. This shall not mean |
6 | the unaltered plant. |
7 | (e)(d) Depressants. Unless specifically excepted or unless listed in another schedule, any |
8 | material, compound, mixture, or preparation that contains any quantity of the following substances |
9 | having a depressant effect on the central nervous system, including its salts, isomers, and salts of |
10 | isomers whenever the existence of the salts, isomers, and salts of isomers is possible within the |
11 | specific chemical designation: |
12 | (1) Mecloqualone. |
13 | (2) Methaqualone. |
14 | (3) 3-methyl fentanyl (n-(3methyl-1(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide. |
15 | (4) 3,4-methyl-enedioxymethamphetamine (MDMA), its optical, positional, and geometric |
16 | isomers, salts, and salts of isomers. |
17 | (5) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical isomers, salts, and salts |
18 | of isomers. |
19 | (6) 1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine (PEPAP), its optical isomers, salts, |
20 | and salts of isomers. |
21 | (7) N-(1-(1-methyl-2-phenyl)ethyl-4-piperidyl)-N-phenyl-acetamide (acetyl- |
22 | alphamethylfentanyl), its optical isomers, salts, and salts of isomers. |
23 | (8) N-(1-(1-methyl-2(2-thienyl)ethyl-4-piperidyl)-N-phenylpropanami de (alpha- |
24 | methylthiofentanyl), its optical isomers, salts, and salts of isomers. |
25 | (9) N-(1-benzyl-piperidyl)-N-phenylpropanamide (benzyl-fentanyl), its optical isomers, |
26 | salts, and salts of isomers. |
27 | (10) N-(1-(2-hydroxy-2-phenyl)ethyl-4-piperidyl)-N-phenyl-propanamid e (beta- |
28 | hydroxyfentanyl), its optical isomers, salts, and salts of isomers. |
29 | (11) N-(3-methyl-1(2-hydroxy-2-phenyl)ethyl-4-piperidyl)-N-phenylpro panamide (beta- |
30 | hydroxy-3-methylfentanyl), its optical and geometric isomers, salts, and salts of isomers. |
31 | (12) N-(3-methyl)-1-(2-(2-thienyl)ethyl-4-piperidyl)-N-phenylpro-panamide (3- |
32 | methylthiofentanyl), its optical and geometric isomers, salts, and salts of isomers. |
33 | (13) N-(1-2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its |
34 | optical isomers, salts, and salts of isomers. |
| LC002079 - Page 6 of 18 |
1 | (14) N-(1-(2(2-thienyl)ethyl-4-piperidyl-N-phenylpropanamide (thiofentanyl), its optical |
2 | isomers, salts, and salts of isomers. |
3 | (15) N-[1-(2-phenylethyl)-4-piperidyl]-N-(4-fluorophenyl)-propanamid e (para- |
4 | fluorofentanyl), its optical isomers, salts, and salts of isomers. |
5 | (16) Gamma hydroxybutyrate, HOOC-CH2-CH2-CH2OH, its optical, position, or |
6 | geometric isomers, salts, and salts of isomers. |
7 | (17) Etizolam. |
8 | (18) Flubromazolam. |
9 | (f)(e) Stimulants. Unless specifically excepted or unless listed in another schedule, any |
10 | material, compound, mixture, or preparation that contains any quantity of the following substances |
11 | having a stimulant effect on the central nervous system, including its salts, isomers, and salts of |
12 | isomers: |
13 | (1) Fenethylline |
14 | (2) N-ethylamphetamine |
15 | (3) 4-methyl-N-methylcathinone (Other name: mephedrone) |
16 | (4) 3,4-methylenedioxy-N-methlycathinone (Other name: methylone) |
17 | (5) 3,4-methylenedioxypyrovalerone (Other name: MDPV) |
18 | (g) Any material, compound, mixture, or preparation that contains any quantity of the |
19 | following substances: |
20 | (1) 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497) |
21 | (2) 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol |
22 | (cannabicyclohexanol and CP-47,497 c8 homologue) |
23 | (3) 1-Butyl-3-(1 naphthoyl)indole, (JWH-073) |
24 | (4) 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) |
25 | (5) 1-Pentyl-3-(1-napthoyl)indole, (JWH-018 and AM678) |
26 | (h)(g) Synthetic cannabinoids or piperazines. Unless specifically excepted, any chemical |
27 | compound which is not approved by the United States Food and Drug Administration or, if |
28 | approved, which is not dispensed or possessed in accordance with state and federal law, that |
29 | contains Benzylpiperazine (BZP); Trifluoromethylphenylpiperazine (TFMPP); 1,1- |
30 | Dimethylheptyl-11-hydroxytetrahydrocannabinol (HU-210); 1-Butyl-3-(1-naphthoyl) indole; 1- |
31 | Pentyl-3-(1-naphthoyl) indole; dexanabinol (HU-211); or any compound in the following structural |
32 | classes: |
33 | (1) Naphthoylindoles: Any compound containing a 3-(1-naphthoyl)indole structure with |
34 | substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, |
| LC002079 - Page 7 of 18 |
1 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
2 | group, whether or not further substituted in the indole ring to any extent and whether or not |
3 | substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not |
4 | limited, to JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, and AM- |
5 | 2201; |
6 | (2) Phenylacetylindoles: Any compound containing a 3-phenylacetylindole structure with |
7 | substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, |
8 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
9 | group whether or not further substituted in the indole ring to any extent and whether or not |
10 | substituted in the phenyl ring to any extent. Examples of this structural class include, but are not |
11 | limited to, JWH-167, JWH-250, JWH-251, and RCS-8; |
12 | (3) Benzoylindoles: Any compound containing a 3-(benzoyl) indole structure with |
13 | substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, |
14 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
15 | group whether or not further substituted in the indole ring to any extent and whether or not |
16 | substituted in the phenyl ring to any extent. Examples of this structural class include, but are not |
17 | limited, to AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4; |
18 | (4) Cyclohexylphenols: Any compound containing a 2-(3-hydroxycyclohexyl)phenol |
19 | structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, |
20 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
21 | group whether or not substituted in the cyclohexyl ring to any extent. Examples of this structural |
22 | class include, but are not limited to, CP 47,497 and its C8 homologue (cannabicyclohexanol); |
23 | (5) Naphthylmethylindoles: Any compound containing a 1H-indol-3-yl-(1-naphthyl) |
24 | methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, |
25 | alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4- |
26 | morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and |
27 | whether or not substituted in the naphthyl ring to any extent. Examples of this structural class |
28 | include, but are not limited to, JWH-175, JWH-184, and JWH-185; |
29 | (6) Naphthoylpyrroles: Any compound containing a 3-(1-naphthoyl)pyrrole structure with |
30 | substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, |
31 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
32 | group whether or not further substituted in the pyrrole ring to any extent and whether or not |
33 | substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not |
34 | limited, to JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368; |
| LC002079 - Page 8 of 18 |
1 | (7) Naphthylmethylindenes: Any compound containing a 1-(1-naphthylmethyl)indene |
2 | structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, |
3 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
4 | group whether or not further substituted in the indene ring to any extent and whether or not |
5 | substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not |
6 | limited to, JWH-176; or |
7 | (8) Any other synthetic cannabinoid or piperazine which is not approved by the United |
8 | States Food and Drug Administration or, if approved, which is not dispensed or possessed in |
9 | accordance with state and federal law. |
10 | (i) Synthetic cathinones. Unless specifically excepted, any chemical compound which is |
11 | not approved by the United States Food and Drug Administration or, if approved, which is not |
12 | dispensed or possessed in accordance with state and federal law, not including bupropion, |
13 | structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, |
14 | naphthyl, or thiophene ring systems, whether or not the compound is further modified in one or |
15 | more of the following ways: |
16 | (1) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, |
17 | haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by |
18 | one or more other univalent substituents. Examples of this class include, but are not limited to, 3,4- |
19 | Methylenedioxycathinone (bk-MDA); |
20 | (2) By substitution at the 3-position with an acyclic alkyl substituent. Examples of this |
21 | class include, but are not limited to, 2-methylamino-1-phenylbutan-1-one (buphedrone); |
22 | (3) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or |
23 | methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure. |
24 | Examples of this class include, but are not limited to, Dimethylcathinone, Ethcathinone, and α- |
25 | Pyrrolidinopropiophenone (α-PPP); or |
26 | (4) Any other synthetic cathinone which is not approved by the United States Food and |
27 | Drug Administration or, if approved, is not dispensed or possessed in accordance with state or |
28 | federal law. Examples of this class include, but are not limited to, Ephylone and Pentylone. |
29 | Schedule II |
30 | (a) Schedule II shall consist of the drugs and other substances, by whatever official name, |
31 | common or usual name, chemical name, or brand name designated, listed in this section. |
32 | (b) Substances, vegetable origin, or chemical synthesis. Unless specifically excepted or |
33 | unless listed in another schedule, any of the following substances whether produced directly or |
34 | indirectly by extraction from substances of vegetable origin, or independently by means of |
| LC002079 - Page 9 of 18 |
1 | chemical synthesis, or by a combination of extraction and chemical synthesis: |
2 | (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or |
3 | opiate excluding naloxone and its salts, and excluding naltrexone and its salts, but including the |
4 | following: |
5 | (i) Raw opium |
6 | (ii) Opium extracts |
7 | (iii) Opium fluid extracts |
8 | (iv) Powdered opium |
9 | (v) Granulated opium |
10 | (vi) Tincture of opium |
11 | (vii) Etorphine hydrochloride |
12 | (viii) Codeine |
13 | (ix) Ethylmorphine |
14 | (x) Hydrocodone |
15 | (xi) Hydromorphone |
16 | (xii) Metopon |
17 | (xiii) Morphine |
18 | (xiv) Oxycodone |
19 | (xv) Oxymorphone |
20 | (xvi) Thebaine |
21 | (2) Any salt, compound, derivative, or preparation that is chemically equivalent or identical |
22 | with any of the substances referred to in subdivision (1) of this subsection, except that these |
23 | substances shall not include the isoquinoline alkaloids of opium. |
24 | (3) Opium poppy and poppy straw. |
25 | (4) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any |
26 | salt, compound, derivative, or preparation that is chemically equivalent or identical with any of |
27 | these substances, except that the substances shall not include decocainized coca leaves or extraction |
28 | of coca leaves, which extractions do not contain cocaine or ecgonine. |
29 | (5) Concentrate of poppy straw (the crude extract of poppy straw in liquid, solid, or powder |
30 | form that contains the phenanthrine alkaloids of the opium poppy). |
31 | (c)(b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the |
32 | following opiates, including its isomers, esters, ethers, salts; and salts of isomers, esters, and ethers |
33 | whenever the existence of the isomers, esters, ethers, and salts is possible within the specific |
34 | chemical designation: |
| LC002079 - Page 10 of 18 |
1 | (1) Alphaprodine |
2 | (2) Anileridine |
3 | (3) Bezitramide |
4 | (4) Dihydrocodeine |
5 | (5) Diphenoxylate |
6 | (6) Fentanyl |
7 | (7) Isomethadone |
8 | (8) Levomethorphan |
9 | (9) Levorphanol |
10 | (10) Metazocine |
11 | (11) Methadone |
12 | (12) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane |
13 | (13) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic |
14 | acid |
15 | (14) Pethidine |
16 | (15) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine |
17 | (16) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate |
18 | (17) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid |
19 | (18) Phenaxocine |
20 | (19) Piminodine |
21 | (20) Racemethorphan |
22 | (21) Racemorphan |
23 | (22) Bulk Dextropropoxyphene (non-dosage forms) |
24 | (23) Suffentanil |
25 | (24) Alfentanil |
26 | (25) Levoalphacetylmethadol |
27 | (26) Carfentanil |
28 | (27) Remifentanil |
29 | (d)(c) Stimulants. Unless specifically excepted or unless listed in another schedule, any |
30 | material, compound, mixture, or preparation that contains any quantity of the following substances |
31 | having a stimulant effect on the central nervous system: |
32 | (1) Amphetamine, its salts, optical isomers, and salts of its optical isomers. |
33 | (2) Methamphetamine, its salts, and salts of its isomers. |
34 | (3) Phenmetrazine and its salts. |
| LC002079 - Page 11 of 18 |
1 | (4) Methylphenidate. |
2 | (e)(d) Depressants. Unless specifically excepted or unless listed in another schedule, any |
3 | material, compound, mixture, or preparation that contains any quantity of the following substances |
4 | having a depressant effect on the central nervous system, including its salts, isomers, and salts of |
5 | isomers whenever the existence of the salts, isomers, and salts of isomers is possible within the |
6 | specific chemical designation: |
7 | (1) Amobarbital |
8 | (2) Glutethimide |
9 | (3) Methyprylon |
10 | (4) Pentobarbital |
11 | (5) Phencyclidine |
12 | (6) Secobarbital |
13 | (7) Phencyclidine immediate precursors: |
14 | (i) 1-phencyclohexylamine |
15 | (ii) 1-piperidinocyclohexane-carbonitrile (PCC) |
16 | (8) Immediate precursor to amphetamine and methamphetamine: Phenylacetone. Some |
17 | other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzone ketone. |
18 | Schedule III |
19 | (a) Unless specifically excepted or unless listed in another schedule, any material, |
20 | compound, mixture, or preparation that contains any quantity of the following substances having a |
21 | depressant effect on the central nervous system: |
22 | (1) Any substance that contains any quantity of a derivative of barbituric acid or any salt |
23 | of a derivative of barbituric acid. |
24 | (2) Chlorhexadol |
25 | (3) Lysergic acid |
26 | (4) Lysergic acid amide |
27 | (5) Sulfondiethylmethane |
28 | (6) Sulfonethylmethane |
29 | (7) Sylfonmethane |
30 | (8) Any compound, mixture, or preparation containing amobarbital, secobarbital, |
31 | pentobarbital, or any salt of them and one or more other active medicinal ingredients that are not |
32 | listed in any schedule. |
33 | (9) Any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or |
34 | any salt of any of these drugs and approved by the Food and Drug Administration for marketing |
| LC002079 - Page 12 of 18 |
1 | only as a suppository. |
2 | (10) Ketamine, its salts, isomers, and salts of isomers. (Some other names for ketamine: |
3 | (+)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone). |
4 | (b) Unless specifically excepted or unless listed in another schedule, any material, |
5 | compound, mixture, or preparation containing limited quantities of any of the following narcotic |
6 | drugs, or any salts of them: |
7 | (1) Not more than one and eight tenths grams (1.8 gms.) of codeine per one hundred |
8 | milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with an equal |
9 | or greater quantity of an isoquinoline alkaloid of opium. |
10 | (2) Not more than one and eight tenths grams (1.8 gms.) of codeine per one hundred |
11 | milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with one or |
12 | more active, nonnarcotic ingredients in recognized therapeutic amounts. |
13 | (3) Not more than three hundred milligrams (300 mgs.) of dihydrocodeinone per one |
14 | hundred milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with |
15 | a fourfold or greater quantity of an isoquinoline alkaloid of opium. |
16 | (4) Not more than three hundred milligrams (300 mgs.) of dihydrocodeinone per one |
17 | hundred milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with |
18 | one or more active nonnarcotic ingredients in recognized therapeutic amounts. |
19 | (5) Not more than one and eight tenths grams (1.8 gms.) of dihydrocodeine per one hundred |
20 | milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with one or |
21 | more active nonnarcotic ingredients in recognized therapeutic amounts. |
22 | (6) Not more than three hundred milligrams (300 mgs.) of ethylmorphine per one hundred |
23 | milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with one or |
24 | more active nonnarcotic ingredients in recognized therapeutic amounts. |
25 | (7) Not more than five hundred milligrams (500 mgs.) of opium per one hundred milliliters |
26 | (100 mls.) or per one hundred grams (100 gms.) or not more than twenty-five milligrams (25 mgs.) |
27 | per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts. |
28 | (8) Not more than fifty milligrams (50 mgs.) of morphine per one hundred milliliters (100 |
29 | mls.) per one hundred grams (100 gms.) with one or more active, nonnarcotic ingredients in |
30 | recognized therapeutic amounts. |
31 | (c) Stimulants. Unless specifically excepted or listed in another schedule, any material, |
32 | compound, mixture, or preparation that contains any quantity of the following substances having a |
33 | stimulant effect on the central nervous system, including its salts, isomers, and salts of the isomers |
34 | whenever the existence of the salts of isomers is possible within the specific chemical designation: |
| LC002079 - Page 13 of 18 |
1 | (1) Benzphetamine |
2 | (2) Chlorphentermine |
3 | (3) Clortermine |
4 | (4) Mazindol |
5 | (5) Phendimetrazine |
6 | (d) Steroids and hormones. Anabolic steroids (AS) or human growth hormone (HGH), |
7 | excluding those compounds, mixtures, or preparations containing an anabolic steroid that because |
8 | of its concentration, preparation, mixture, or delivery system, has no significant potential for abuse, |
9 | as published in 21 C.F.R. § 1308.34, including, but not limited to, the following: |
10 | (1) Chorionic gonadotropin, except for veterinary use and when that use is approved by the |
11 | Food and Drug Administration. |
12 | (2) Clostebol |
13 | (3) Dehydrochlormethyltestosterone |
14 | (4) Ethylestrenol |
15 | (5) Fluoxymesterone |
16 | (6) Mesterolone |
17 | (7) Metenolone |
18 | (8) Methandienone |
19 | (9) Methandrostenolone |
20 | (10) Methyltestosterone |
21 | (11) Nandrolone decanoate |
22 | (12) Nandrolone phenpropionate |
23 | (13) Norethandrolone |
24 | (14) Oxandrolone |
25 | (15) Oxymesterone |
26 | (16) Oxymetholone |
27 | (17) Stanozolol |
28 | (18) Testosterone propionate |
29 | (19) Testosterone-like related compounds |
30 | (20) Human Growth Hormone (HGH) |
31 | (e) Hallucinogenic substances. |
32 | (1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in U.S. |
33 | Food and Drug Administration-approved drug product. (Some other names for dronabinol: (6aR- |
34 | trans)-6a, 7, 8, 10a-tetrahydro-6, 6, 9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or (-)-delta- |
| LC002079 - Page 14 of 18 |
1 | 9(trans)-tetrahydrocannabinol.) |
2 | Schedule IV |
3 | (1) Barbital. |
4 | (2) Chloral betaine |
5 | (3) Chloral hydrate |
6 | (4) Ethchrovynol |
7 | (5) Ethinamate |
8 | (6) Methohexital |
9 | (7) Meprobamate |
10 | (8) Methylphenobarbital |
11 | (9) Paraldehyde |
12 | (10) Petrichloral |
13 | (11) Phenobarbital |
14 | (12) Fenfluramine |
15 | (13) Diethylpropion |
16 | (14) Phentermine |
17 | (15) Pemoline (including organometallic complexes and chelates thereof). |
18 | (16) Chlordiazepoxide |
19 | (17) Clonazepam |
20 | (18) Clorazepate |
21 | (19) Diazepam |
22 | (20) Flurazepam |
23 | (21) Mebutamate |
24 | (22) Oxazepam |
25 | (23) Unless specifically excepted or unless listed in another schedule, any material, |
26 | compound, mixture, or preparation that contains any quantity of the following substances, including |
27 | its salts: |
28 | Dextropropoxyphene(alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propronox |
29 | ybutane). |
30 | (24) Prazepam |
31 | (25) Lorazepam |
32 | (26) Not more than one milligram (1 mg.) of difenoxin and not less than twenty-five (25) |
33 | micrograms of atropine sulfate per dosage unit. |
34 | (27) Pentazocine |
| LC002079 - Page 15 of 18 |
1 | (28) Pipradrol |
2 | (29) SPA (-)-1-dimethylamino-1, 2-diphenylethane |
3 | (30) Temazepam |
4 | (31) Halazepam |
5 | (32) Alprazolam |
6 | (33) Bromazepam |
7 | (34) Camazepam |
8 | (35) Clobazam |
9 | (36) Clotiazepam |
10 | (37) Cloxazolam |
11 | (38) Delorazepam |
12 | (39) Estazolam |
13 | (40) Ethyl Ioflazepate |
14 | (41) Fludizaepam |
15 | (42) Flunitrazepam |
16 | (43) Haloxazolam |
17 | (44) Ketazolam |
18 | (45) Loprazolam |
19 | (46) Lormetazepam |
20 | (47) Medazepam |
21 | (48) Nimetazepam |
22 | (49) Nitrazepam |
23 | (50) Nordiazepam |
24 | (51) Oxazolam |
25 | (52) Pinazepam |
26 | (53) Tetrazepam |
27 | (54) Mazindol |
28 | (55) Triazolam |
29 | (56) Midazolam |
30 | (57) Quazepam |
31 | (58) Butorphanol |
32 | (59) Sibutramine |
33 | (60) Tramadol |
34 | (61) Zolpidem |
| LC002079 - Page 16 of 18 |
1 | Schedule V |
2 | (a) Any compound, mixture, or preparation containing any of the following limited |
3 | quantities of narcotic drugs, which shall include one or more non-narcotic active medicinal |
4 | ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable |
5 | medicinal qualities other than those possessed by the narcotic drug alone: |
6 | (1) Not more than two hundred milligrams (200 mgs.) of codeine per 100 milliliters (100 |
7 | mls.) or per one hundred grams (100 gms.). |
8 | (2) Not more than one hundred milligrams (100 mgs.) of dihydrocodeine per 100 milliliters |
9 | (100 mls.) or per one hundred grams (100 gms.). |
10 | (3) Not more than one hundred milligrams (100 mgs.) of ethylmorphine per 100 milliliters |
11 | (100 mls.) or per one hundred grams (100 gms.). |
12 | (4) Not more than two and five tenths milligrams (2.5 mgs.) of diphenixylate and not less |
13 | than twenty-five (25) micrograms of atropine sulfate per dosage unit. |
14 | (5) Not more than one hundred milligrams (100 mgs.) of opium per one hundred milliliters |
15 | (100 mls.) or per one hundred grams (100 gms.). |
16 | (b) Not more than five tenths milligrams (0.5 mgs.) of difenoxin and not less than twenty- |
17 | five (25) micrograms of atropine sulfate per dosage unit. |
18 | (c) Buprenorphine |
19 | (d) Unless specifically exempted or excluded or unless listed in another schedule, any |
20 | material, compound, mixture, or preparation that contains any quantity of the following substances |
21 | having a stimulant effect on the central nervous system, including its salts, isomers, and salts of |
22 | isomers: |
23 | (1) Propylhexedrine (except as benzedrex inhaler) |
24 | (2) Pyrovalerone. |
25 | (e) Xylazine HCL |
26 | SECTION 2. This act shall take effect upon passage. |
======== | |
LC002079 | |
======== | |
| LC002079 - Page 17 of 18 |
EXPLANATION | |
BY THE LEGISLATIVE COUNCIL | |
OF | |
A N A C T | |
RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT | |
*** | |
1 | This act would provide that Schedules I through V of the Uniform Controlled Substances |
2 | Act consist of drugs and other substances, by whatever official name, common or usual name, |
3 | chemical name or name designated by the director of the department of health, and would add |
4 | several new drugs to various schedules, including Etizolam, Flubromazolam, Tramadol, Zolpidem, |
5 | and Xylazine HCL. |
6 | This act would take effect upon passage. |
======== | |
LC002079 | |
======== | |
| LC002079 - Page 18 of 18 |